A significant change is under way as the industry shifts from passive to active trial master file (TMF) management, writes Rik van Mol.
The pharma industry has had a year to address MHRA’s April 2014 update to the definition of a critical GCP inspection finding to include trial master files(TMFs) that are “not readily available or accessible”. How has it fared? Rik van Mol reports.